Anti-CCL2 (Carlumab) -MC-Vc-PAB-SN38

Anti-CCL2 (Carlumab) -MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704) . The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057) . Anti-CCL2 (Carlumab) -MC-Vc-PAB-SN38 can be used in cancer research[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; CCR; Topoisomerase

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-CCL2(Carlumab)-MC-Vc-PAB-SN38]

References & Citations

[1]Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53 (10) :1020-7.|[2]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16 (5) :315-337.